Vertex Pharmaceuticals Overview
Vertex Pharmaceuticals Target Price
Analysts' 12-month price predictions for VRTX.
Share Price
$443.54
Average Target Price
$465.67
5% upside
5% upside3 analysts in the last 4 months
High: $535 | Low: $420
Analyst Recommendations
No recommendations in the last 4 months.
Revenue & Income Forecast
Analysts' Target Prices
| Date | Analyst | Price Target | Current Upside/Downside | |
|---|---|---|---|---|
| 2025-06-17 | RBC CapitalBrian Abrahams | $420 |  5.3% downside |  |
| 2025-05-06 | ScotiabankGreg Harrison | $442 | 0.3% downside | |
| 2025-04-22 | Cantor Fitzgerald | $535 | 20.6% upside | |
| 2025-01-31 | BMO CapitalEvan Seigerman | $545 | 22.9% upside | |
| 2025-01-30 | Wells FargoMohit Bansal | $460 | 3.7% upside | |
| 2025-01-10 | Morgan StanleyTerence Flynn | $456 | 2.8% upside | |
| 2024-12-19 | RBC CapitalBrian Abrahams | $400 | 9.8% downside | |
| 2024-12-09 | JefferiesMichael Yee | $550 | 24% upside | |
| 2024-11-05 | OppenheimerHartaj Singh | $540 | 21.7% upside | |
| 2024-11-05 | RBC CapitalBrian Abrahams | $451 | 1.7% upside | |
| 2024-10-22 | Canaccord GenuityWhitney Ijem | $361 | 18.6% downside | |
| 2024-10-21 | BMO CapitalEvan David Seigerman | $566 | 27.6% upside | |
| 2024-10-21 | Goldman SachsSalveen Richter | $598 | 34.8% upside | |
| 2024-10-14 | Bank of America SecuritiesGeoff Meacham | $541 | 22% upside | |
| 2024-10-09 | RBC CapitalBrian Abrahams | $437 | 1.5% downside | |
| 2024-08-05 | Truist FinancialJoon Lee | $550 | 24% upside | |
| 2024-08-05 | OppenheimerHartaj Singh | $550 | 24% upside | |
| 2024-08-05 | Wolfe ResearchAndy Chen | $576 | 29.9% upside | |
| 2024-08-02 | H.C. WainwrightAndrew Fein | $600 | 35.3% upside | |
| 2024-06-17 | Argus ResearchJasper Hellweg | $550 | 24% upside | |
| 2024-06-11 | RBC CapitalBrian Abrahams | $421 | 5.1% downside | |
| 2024-05-31 | BMO CapitalEvan David Seigerman | $500 | 12.7% upside | |
| 2024-05-07 | Raymond JamesChristopher Raymond | $456 | 2.8% upside | |
| 2024-05-07 | RBC CapitalBrian Abrahams | $424 | 4.4% downside | |
| 2024-04-11 | H.C. WainwrightAndrew Fein | $462 | 4.2% upside | |
| 2024-04-11 | Evercore ISILiisa Bayko | $438 | 1.2% downside | |
| 2023-02-08 | Morgan Stanley | $285 | 35.7% downside | |
| 2023-02-08 | H.C. Wainwright | $326 | 26.5% downside | |
| 2023-02-08 | Leerink Partners | $365 | 17.7% downside | |
| 2022-11-17 | Argus Research | $340 | 23.3% downside | |
| 2022-08-08 | Morgan Stanley | $253 | 43% downside | |
| 2022-08-05 | H.C. Wainwright | $300 | 32.4% downside | |
| 2022-07-12 | Cantor FitzgeraldOlivia Brayer | $365 | 17.7% downside | |
| 2022-07-11 | Stifel NicolausPaul Matteis | $240 | 45.9% downside | |
| 2022-07-02 | Argus ResearchJasper Hellweg | $280 | 36.9% downside | |
| 2022-06-13 | Cowen & Co. | $310 | 30.1% downside | |
| 2022-05-03 | Morgan StanleyMatthew Harrison | $250 | 43.6% downside | |
| 2022-04-22 | Piper Sandler | $249 | 43.9% downside | |
| 2022-04-06 | OppenheimerHartaj Singh | $350 | 21.1% downside | |
| 2022-03-22 | Robert W. BairdBrian Skorney | $240 | 45.9% downside | |
| 2022-03-22 | BMO CapitalEvan Seigerman | $274 | 38.2% downside | |
| 2022-01-27 | J.P. MorganCory Kasimov | $288 | 35.1% downside | |
| 2022-01-27 | Wolfe ResearchAndrew Galler | $282 | 36.4% downside | |
| 2022-01-27 | Morgan StanleyMatthew Harrison | $208 | 53.1% downside | |
| 2022-01-27 | JefferiesMichael Yee | $275 | 38% downside | |
| 2022-01-24 | Cowen & Co.Phil Nadeau | $300 | 32.4% downside | |
| 2021-12-02 | Leerink PartnersGeoff Porges | $175 | 60.5% downside | |
| 2021-12-01 | GuggenheimDebjit Chattopadhyay | $286 | 35.5% downside | |
| 2021-11-02 | Bank of America SecuritiesGeoff Meacham | $275 | 38% downside | |
| 2021-06-11 | BarclaysGena Wang | $285 | 35.7% downside | |